Damora Therapeutics (DMRA)General Counsel sold ~$881

~$881

Approx. value · 260 sh @ $3.39

1,429

Holds after · shares reported

Traded

Jul 3, 2025

Filed

Jul 8, 2025

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Jul 3, 2025 · this disclosureInsiderOfficer sold ~$881 of DMRA shares in the open market

What came next

1. Jul 3, 2025Insider · 2 peopleInsiders: 2 sales (~$3K)

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Damora Therapeutics

For Damora Therapeutics, OQRO holds 1 insider filing (SEC Form 4 or Form 144) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its DMRA page.

Other recent filings by Garrett Winslow, General Counsel

• SEC Form 4 at Damora Therapeutics (DMRA)Jan 7, 2025

The full history of Garrett Winslow, General Counsel is on the profile page.

How this filing works

• SEC Form 4
• Open-market purchase
• Rule 10b5-1 trading plans

Other disclosures at Damora Therapeutics

• SEC Form 4Sep 28, 2026
• SEC Form 4Jul 8, 2025
• SEC Form 4Jul 8, 2025
• SEC Form 4Jan 7, 2025
• SEC Form 4Jan 7, 2025
• SEC Form 4Jan 7, 2025

Everything OQRO holds on this company is on its DMRA page.